Price Alert

Terns Pharmaceuticals Inc... (TERN)

NASDAQ: TERN · Real-Time Price · USD

7.22

0.16 (2.27%)

At close: Sep 05, 2025, 3:59 PM

7.22

0.00%

After-hours: Sep 05, 2025, 05:26 PM EDT

2.27% (1D)

Bid	6.78
Market Cap	631.83M
Revenue (ttm)	n/a
Net Income (ttm)	-91.75M
EPS (ttm)	-0.98
PE Ratio (ttm)	-7.37
Forward PE	-6.05
Analyst	Buy

Ask	7.44
Volume	755,943
Avg. Volume (20D)	1,056,969
Open	7.08
Previous Close	7.06
Day's Range	6.97 - 7.27
52-Week Range	1.86 - 11.40
Beta	-0.06

About TERN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TERN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TERN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 months ago

-5.64%

TERN stock has given up its prior gain. Terns Phar... Unlock content with Pro Subscription

2 months ago

-5.64%

Terns Pharmaceuticals shares are trading higher after the company announced it will highlight data from the completed Phase 1 study of TERN-601 at the American Diabetes Association 85th Scientific Sessions. Also, the company completed enrollment for the Phase 2 FALCON trial.

News

1 day ago · https://thefly.com

Terns Pharmaceuticals assumed with a Neutral at H.C. Wainwright

H.C. Wainwright assumed coverage of Terns Pharmaceuticals with a Neutral rating and $7.44 price target. The firm is cautiously optimistic on TERN-701 and TERN-601 as it awaits "differentiation data." ...

2 days ago · seekingalpha.com

Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript

Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript Company Participants Amy Burroughs - CEO & Director Emil Kuriakose - Chief Medical Officer Scott Harris - Chief Developme...

1 month ago · fool.com

Terns (TERN) Q2 Net Loss Narrows 16%

1 month ago · seekingalpha.com

Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts

Terns Pharmaceuticals, Inc. offers two differentiated late-stage assets—TERN-701 for CML and TERN-601 for obesity—with major data catalysts expected in Q4 2025. TERN-701 shows early signs of best-in-c...

2 months ago · 247wallst.com

3 Penny Stocks Wall Street Sees With 243% Upside

“The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.

2 months ago · https://www.defenseworld.net

Squarepoint Ops LLC Has $73,000 Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)

Squarepoint Ops LLC cut its holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Free Report) by 75.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institu...